VEGFA and hepatocellular carcinoma: Moreover, the efficacy of immunotherapy has been cemented in HCC treatment through the combination of the anti-PD-L1 agent atezolizumab and the anti-vascular endothelial growth factor (VEGF) agent bevacizumab, which gradually becomes a first-line choice [13].